Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 1824-1828, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mercer, D. W.
Right arrow Articles by Talamo, T. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mercer, D. W.
Right arrow Articles by Talamo, T. S.

Clinical Chemistry, Vol 31, 1824-1828, Copyright © 1985 by American Association for Clinical Chemistry

Multiple markers of malignancy in sera of patients with colorectal carcinoma: preliminary clinical studies

DW Mercer and TS Talamo

Eleven potential biochemical markers were measured in serum from 33 patients with malignant and 13 with benign colorectal disease: four isoenzymes (creatine kinase-BB, homoarginine-sensitive alkaline phosphatase, salivary-type amylase, and macro-creatine kinase type 2), five specific proteins (ferritin, alpha 1-acid glycoprotein, C-reactive protein, alpha 1-antitrypsin, and ceruloplasmin), one oncofetal antigen (carcinoembryonic antigen, CEA), and one hormone (beta human choriogonadotropin). The sensitivity of individual markers for the detection of early-stage malignancy (n = 11) ranged from 0% to 64% (CEA 18%); for late-stage colon malignancy (n = 12) from 8% to 83% (CEA 83%). Specificity in patients (n = 10) with benign intestinal disease ranged from 80% to 100% (CEA 100%). The five most-sensitive markers--C- reactive protein, alpha 1-glycoprotein, CEA, macrocreatine kinase type 2, and homoarginine-sensitive alkaline phosphatase--were selected for use as a "colon panel." In retrospective comparison, use of the colon panel instead of CEA alone increased sensitivity by 17% and 64% for late-and early-stage cancer, respectively; specificity, however, decreased by 30%, but should improve with serial testing.


The following articles in journals at HighWire Press have cited this article:


Home page
 QJMHome page
D. Mazhar and S. Ngan
C-reactive protein and colorectal cancer.
QJM, August 1, 2006; 99(8): 555 - 559.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Balasubramani, B. W. Day, R. E. Schoen, and R. H. Getzenberg
Altered Expression and Localization of Creatine Kinase B, Heterogeneous Nuclear Ribonucleoprotein F, and High Mobility Group Box 1 Protein in the Nuclear Matrix Associated with Colon Cancer
Cancer Res., January 15, 2006; 66(2): 763 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. M. Harman, F. Gucciardo, C. B. Heward, P. Granstrom, B. Barclay-White, L. W. Rogers, and J. A. Ibarra Jr.
Discrimination of Breast Cancer by Anti-Malignin Antibody Serum Test in Women Undergoing Biopsy
Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2310 - 2315.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. M. Zhang, J. E. Buring, I-M. Lee, N. R. Cook, and P. M. Ridker
C-Reactive Protein Levels Are Not Associated with Increased Risk for Colorectal Cancer in Women
Ann Intern Med, March 15, 2005; 142(6): 425 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
B. Galarraga, D. Sinclair, M. N. Fahie-Wilson, F. C. McCrae, R. G. Hull, and J. M. Ledingham
A rare but important cause for a raised serum creatine kinase concentration: two case reports and a literature review
Rheumatology, January 1, 2003; 42(1): 186 - 188.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. Moulton, P. H. Yoshihara, D. H. Mason, P. L. Iversen, and P. L. Triozzi
Active Specific Immunotherapy with a {beta}-Human Chorionic Gonadotropin Peptide Vaccine in Patients with Metastatic Colorectal Cancer: Antibody Response Is Associated with Improved Survival
Clin. Cancer Res., July 1, 2002; 8(7): 2044 - 2051.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.